BioCentury | Apr 22, 2019
Distillery Therapeutics

STAG2 identified as target in glioblastoma and Ewing sarcoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer; sarcoma Cell culture studies suggest inhibiting STAG2 could sensitize glioblastoma and Ewing sarcoma to agents that disrupt repair of DNA double-strand (dsDNA) breaks. In two human glioblastoma and one...
BioCentury | Dec 5, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell studies suggest PARP inhibitors and other inhibitors of DNA damage repair could help treat brain cancers that have complex genome rearrangements (chromothripsis). In mouse medulloblastoma cells with homozygous XRCC4 deletion-induced chromothripsis,...
BioCentury | Nov 29, 2018
Translation in Brief

Beyond BRCA

Researchers at the German Cancer Research Center have identified synthetic lethal markers beyond BRCA that expand the pool of patients who may benefit from PARP inhibitors and other compounds targeting DNA damage repair pathways. In...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
BioCentury | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Mar 16, 2018
Finance

Following its blueprint

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round. Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors...
BioCentury | Mar 16, 2018
Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round on March 15 led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche...
BioCentury | Mar 15, 2018
Financial News

Synthetic lethality company Ideaya raises $94M

Ideaya Biosciences Inc. (South San Francisco, Calif.) raised $94 million in a series B round led by Nextech Invest, 6 Dimensions Capital, BVF Partners and Perceptive Advisors. Fellow new investors GV, Roche Venture Fund, Boxer...
BioCentury | Apr 7, 2016
Translation in Brief

Knowing when to fold

A team from the Flanders Institute for Biotechnology (VIB) has linked two genes involved in the unfolded protein stress response to the fragility of pancreatic β cells involved in both Type I and Type II...
BioCentury | Jan 21, 2016
Distillery Techniques

Techniques: Live-cell, fluorescence-based method to identify optimal reporter cell lines for compound screening

Assays and screens TECHNOLOGY: High throughput screening A fluorescence-based method in live cells could help identify optimal reporter cell lines for screening compound libraries. The method involved generating a library of reporter cell lines, and...
Items per page:
1 - 10 of 14